The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

solasia.co.jp

Stage

IPO | IPO

Total Raised

$7.8M

Date of IPO

3/23/2017

Market Cap

11.61B

About Solasia Pharma

Solasia Pharma, formerly known as JapanBridge, expedites patient access to unique oncology therapies through aggressive development and specialized commercialization throughout Japan, China and other Asian countries. Solasia has Asian rights to Sancuso (extended release granisetron transdermal patch) from ProStrakan Group plc and an exclusive license to ZIOPHARM's SP-02 / darinaparsin, in major Asian countries. Solasia is currently conducting a Phase 1 study of darinaparsin in PTCL in Japan and Korea.

Solasia Pharma Headquarter Location

3F, Shiodome Building 1-2-20, Kaigan, Minato-ku,

Tokyo, 105-0022,

Japan

+81 3 6721 8332

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Solasia Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Solasia Pharma is included in 2 Expert Collections, including Cancer.

C

Cancer

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Solasia Pharma Patents

Solasia Pharma has filed 5 patents.

The 3 most popular patent topics include:

  • Antineoplastic drugs
  • Experimental cancer drugs
  • Monoclonal antibodies
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/15/2020

5/10/2022

Experimental cancer drugs, Transcription factors, Oncology, Antineoplastic drugs, Monoclonal antibodies

Grant

Application Date

10/15/2020

Grant Date

5/10/2022

Title

Related Topics

Experimental cancer drugs, Transcription factors, Oncology, Antineoplastic drugs, Monoclonal antibodies

Status

Grant

Latest Solasia Pharma News

Solasia and Nippon Kayaku Announce License Agreement in Japan for New Drug Candidate DARINAPARSIN (SP-02)

Nov 2, 2021

TOKYO--(BUSINESS WIRE)--Solasia Pharma K.K. (TOKYO: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) and Nippon Kayaku Co., Ltd. (TOKYO: 4272, Headquarters: Tokyo, Japan, President: Atsuhiro Wakumoto) today jointly announced the conclusion of a license agreement for marketing rights to darinaparsin (generic name, development code: SP-02) in Japan (hereinafter “this agreement”). Darinaparsin is a drug candidate under development by Solasia for rela...

Solasia Pharma Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Solasia Pharma Rank

  • Where is Solasia Pharma's headquarters?

    Solasia Pharma's headquarters is located at 3F, Shiodome Building, Tokyo.

  • What is Solasia Pharma's latest funding round?

    Solasia Pharma's latest funding round is IPO.

  • How much did Solasia Pharma raise?

    Solasia Pharma raised a total of $7.8M.

  • Who are Solasia Pharma's competitors?

    Competitors of Solasia Pharma include Ology Bioservices, Adastra Pharmaceuticals, Salix Pharmaceuticals, ANI Pharmaceuticals, Supernus Pharmaceuticals and 11 more.

You May Also Like

A
Alinea Pharmaceuticals

Alinea Pharmaceuticals, Inc. offers pharmaceuticals for diabetes and related metabolic disorders

B
Bluefish Pharmaceuticals

Bluefish Pharmaceuticals offers a range of quality pharmaceuticals at prices that as many as possible will be able to afford.

G
Greystone Pharmaceuticals

Greystone Pharmaceuticals is a healthcare company focused on wound technologies.

Z
Zebra Pharmaceuticals

Zebra Pharmaceuticals offers customized health products through nature and science.

A
Arriva Pharmaceuticals

Arriva Pharmaceuticals, Inc. offers enzyme inhibitor replacement & therapy

A
Ausio Pharmaceuticals

Ausio Pharmaceuticals is a company focused on the clinical development of S-Equol for major medical needs.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.